Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus THIOTHIXENE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus THIOTHIXENE HYDROCHLORIDE.
FLUPHENAZINE DECANOATE vs THIOTHIXENE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic. It exerts its effects by blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway, and also has antagonistic activity at alpha-1 adrenergic, muscarinic, and histamine H1 receptors, contributing to its side effect profile.
Thiothixene hydrochloride is a typical antipsychotic that blocks postsynaptic dopamine D2 receptors in the central nervous system (CNS), particularly in the mesolimbic and mesocortical pathways. It also has alpha-adrenergic blocking activity and weak anticholinergic effects.
12.5-25 mg deep IM injection every 2-4 weeks, not exceeding 100 mg per dose.
Initial: 2-5 mg orally 3 times daily; maintenance: 15-30 mg orally per day in divided doses; maximum: 60 mg orally per day.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 7-21 days) following IM injection, reflecting slow release from depot and prolonged redistribution.
Terminal elimination half-life: 34 hours (range 25–50 hrs) in adults; clinical context: allows once-daily dosing.
Primarily renal (metabolites) and fecal (biliary). Estimated 50% renal, 50% fecal as metabolites.
Renal: primarily as metabolites, <1% unchanged; fecal: minor; biliary: some metabolites excreted in bile.
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic